HOME >> BIOLOGY >> NEWS
NIAID supports research into etiology of fungal-induced inflammation in chronic sinusitis

ce, associate professor at VBI, will head the work at VBI in collaboration with VBI assistant professor Dharmendar Rathore. Researchers at Mayo, including clinical assistant professor Jens Ponikau, who is now at the University at Buffalo School of Medicine & Biomedical Sciences, and Hirohito Kita, professor of Immunology and the director of the Allergic Diseases Laboratory at Mayo, carried out extensive research at the Mayo Clinic which identified a fungal origin for CS.

Accentia Biopharmaceuticals is commercializing a diagnostic and developing a treatment for CS based on the published technology discovered at the Mayo Clinic. Investigators at Mayo discovered that a ubiquitous, normally innocuous mold, Alternaria, colonizes the mucus of the nose and sinus of virtually everybody, but in patients with CS, this non-invasive mold elicits an eosinophilic inflammatory response characterized by release of eosinophil major basic protein (eMBP) in the mucus, which then damages the mucosal epithelial lining of the nose and sinuses and leads to the inflammatory mucosal changes characteristic of CS.

Dr. Jens Ponikau, Assistant Professor of Clinical Otolaryngology, University at Buffalo, commented: Research supported by the National Institutes of Health had previously shown that CS patients have an exaggerated immune response to certain fungi, specifically Alternaria species. The patients reacted to the fungi with the production of the inflammatory mediators, which are crucial for the inflammation in CS, whereas healthy subjects were not reacting. The renewal of the NIH grant will allow Dr. Kita and Dr. Lawrence to further pinpoint the mechanism by which the fungus causes the inflammation, and specifically what fungal products are involved. Both are important milestones to deepen our understanding about CS, and will help us to better understand the mechanism of action of newer treatment approaches, such as anti-fungal therapy.

As previously an
'"/>

Contact: Janet Vasquez
jvasquez@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
1-Jun-2007


Page: 1 2 3

Related biology news :

1. US government $20M NIAID grant funds Proteome Systems catalytic scavenger compounds
2. ESA open-source software supports Germanys TerraSAR-X
3. National Science Foundation supports UCR study of polar lake life forms
4. Hofmeyr skull supports the Out of Africa theory
5. USC study in Nature Genetics supports a stem cell origin of cancer
6. AIUM supports FDA decision to deny over-the-counter use of handheld doppler fetoscopes
7. Conference supports minority students to pursue biomedical careers
8. Study supports urgent need for worldwide ban on lead-based paint
9. Slow-frozen people? Latest research supports possibility of cryopreservation
10. Award supports Virginia Tech research to reduce vehicle emissions, create biofuel
11. Taxpayer Alliance supports senate bill broadening access to federal research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/16/2017)... -- CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog ... Used combined in one project, multi-biometric solutions provide ... ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ex-FDA official ... trials comes to Tampa, San Francisco and Boston in 2017. The 2016 ... organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix Inc., Cell ...
(Date:4/26/2017)... 2017  Genisphere LLC, provider of the 3DNA ... collaborative and sponsored research agreement with the University ... The overall goal of the partnership is to ... designs and formulations after in vivo ... vasculature as well as inflammatory responses, demonstrating various ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... & Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, MD, ... on May 15, 2017. , Dr. Terzella completed his residency in Physical Medicine ...
(Date:4/21/2017)... ... April 21, 2017 , ... The ... 10 categories with over 30 nominees and well as the first-year award for ... award and the event was hosted by CompanyWeek and Manufacturers Edge, among other ...
Breaking Biology Technology:
Cached News: